SOU-001

SOU-001 is a discontinued small molecule drug candidate that was developed by Nxera Pharma (formerly known as Sosei Heptares). It functions as a dual antagonist of the alpha-1A (α1A-AR) and alpha-1B (α1B-AR) adrenergic receptors. These G protein-coupled receptors (GPCRs) are primarily involved in the contraction of smooth muscle in response to catecholamines like norepinephrine. While alpha-1 adrenergic receptor antagonists are commonly utilized in the management of conditions such as benign prostatic hyperplasia (BPH) and hypertension, the specific clinical indications for SOU-001 were not publicly detailed prior to the discontinuation of its development program.